METHOD FOR COATING A GLASS SYRINGE BODY FOR A HYPODERMIC PRE-MADE GLASS SYRINGE, HYPODERMIC PRE-MADE GLASS SYRINGE AND PLASMA TREATMENT DEVICE FOR GLASS SYRINGE BODY OF HYPODERMIC PRE-MADE GLASS SYRINGES

Description

[0001] The present invention relates to a method for coating a glass syringe body for a hypodermic pre-filled glass syringe. Furthermore, the present invention relates to a hypodermic pre-filled glass syringe. Furthermore, the present invention also relates to a plasma treatment device for glass syringe bodies of hypodermic pre-filled glass syringes.

[0002] Hypodermic pre-filled glass syringes are generally intended for use on a patient's skin, in particular to penetrate the subcutaneous tissue. Such syringes typically comprise an elongated, cylindrical sleeve with two diametrically opposed ends and a chamber formed between the two ends for storing a substance, for example a fluid, preferably containing an active ingredient. One of the two ends has an opening to allow the insertion of a plunger and, if appropriate, a flange for finger actuation by a user. The other of the two ends typically tapers in cross-section to form a syringe cone and is essentially closed except for a narrow passage or end channel extending from the sleeve chamber through the syringe cone and allowing the substance to exit or be expelled from the chamber through the syringe cone.A cannula can be attached to the end of the syringe cone, for example, by means of an adhesive. Alternatively, the cannula can also be attached externally to the barrel body using a cannula holder. A cannula is generally understood to be a hollow needle used to penetrate human or animal tissue in order to inject fluid or withdraw body fluids with the aid of the syringe.

[0003] It is known to provide a glass syringe with a lubricant layer, such as a silicone layer, on the inside. This is done to reduce friction between the plunger and the inner surface of the sleeve body, making it easier to move the plunger relative to the sleeve body, and to ensure a fully circumferential sealing contact surface simply between the hard inside of the glass body and the hard outside of the plunger due to the deformability of the lubricant layer. There are basically two options. Firstly, the glass syringe can be coated with a lubricant layer on the inside, for example using oily silicone. In this case, the cannula is glued in before being coated with the lubricant layer. Another option is baked-on siliconization, which is used particularly when a harder adhesion of the silicone oil to the syringe is required.In this context, baking is understood as hardening. However, with this technique, it is not possible to break in the cannula before siliconization, as the cannula cannot withstand the high temperatures encountered during baking siliconization. Thus, the previously unsolved problem in the field of glass syringes with a lubricant inner layer, especially with baking siliconized glass syringes, of bonding a cannula in the end channel of the glass syringe with sufficient adhesion and strength properties remains. It has been shown that sufficient adhesion between the adhesive and the glass cannot be established due to the presence of the silicone layer.

[0004] One solution to this problem is to make a silicone layer adhesive by using atmospheric plasma to pretreat the adhesive layer. However, due to the dimensional nature of the glass syringe, especially in the area of ​​the inner channel at the end, it is not possible to ensure complete plasma access to the lubricant layer, thus ensuring reliable adhesion of the cannula in the end channel.

[0005] EP 1 352 667, for example, discloses a method for manufacturing an injection syringe, in which a syringe body is provided with a lubricant at high temperature. The lubricant is subsequently removed at the joint between the syringe body and the cannula, for example, by plasma treatment, to enable the adhesive used for joining to adhere to the inner surface of the syringe body and thus the cannula to the syringe body. This known method has the disadvantage that complete removal of the lubricant in the spatially confined area at the tip of the sleeve body can only be achieved with great effort.

[0006] WO 2011 / 029628 A1 discloses a pharmaceutical packaging material with a lubricating film and a method for its production. Furthermore, WO 2007 / 137890 A1 discloses a method and a device for surface treatment of containers or objects.

[0007] It is therefore an object of the invention to overcome the disadvantages of the known prior art, in particular to provide a method for coating a glass syringe body provided with an inner lubricant layer, in particular siliconized or baked-on siliconized, for a hypodermic pre-filled glass syringe, in which the holding force between the cannula and the glass syringe body is increased, in particular in order to achieve holding forces according to DIN ISO 7864, and in which the narrow end channel of the glass syringe can be subjected to an improved treatment with atmospheric plasma. It is also an object of the present invention to provide a hypodermic pre-filled glass syringe that has an increased holding force between the glass syringe and cannula and is subjected to an improved treatment with atmospheric plasma.Furthermore, it is an object of the present invention to provide a plasma treatment device for a glass syringe body of a hypodermic pre-filled glass syringe, with which an increased holding force between the cannula and the glass syringe body can be achieved and an improved treatment with atmospheric plasma can be carried out.

[0008] This problem is solved by the features of the independent claims.

[0009] According to this, a method for coating a glass syringe body for a hypodermic pre-filled glass syringe is proposed, in which at least one emulsion and / or a solution containing at least one layer-forming substance is applied to at least one inner surface of the hypodermic pre-filled glass syringe. The pre-filled glass syringe defines an axial direction that runs essentially parallel to a longitudinal direction of the pre-filled glass syringe. The hypodermic pre-filled glass syringe can have a flat or curved inner surface. In particular, the hypodermic glass syringe can initially be a semi-finished product that is further processed into a finished product in subsequent process steps. In other embodiments of the invention, the hypodermic glass syringe can also be designed as a finished product that requires no further processing after the proposed coating process has been carried out.

[0010] The coating contains at least one layer-forming substance, which is present in the form of an emulsion and / or a solution. In addition to the layer-forming substance, the emulsion or solution contains at least one solvent. For the purposes of this description, the carrier matrix of an emulsion is also referred to as a solvent, even if the layer-forming substances are only emulsified and not dissolved in the strict sense.

[0011] The emulsion or solution can be applied to at least one inner surface of the hypodermic pre-filled glass syringe by methods known per se. For example, a full coating of the hypodermic pre-filled glass syringe can also be provided, i.e., the entire inner surface of the hypodermic pre-filled glass syringe is coated. The emulsion or solution can be applied, for example, by spraying, printing, brushing, or dipping. To enable a more uniform coating with the emulsion or solution, additional measures can be taken, for example, reducing the viscosity by heating and / or dilution or assisting the coating with electric fields, as in electrocoating.

[0012] The hypodermic pre-filled glass syringe can be heat-treated after application of the emulsion or solution. The heat treatment can be carried out immediately after application of the emulsion or solution. For example, the heat treatment can be performed after a prior drying step. The heat treatment leads, on the one hand, to the solvent of the emulsion or solution evaporating or being expelled from the layer. Furthermore, a bond can be formed between the layer-forming substances and the inner surface of the hypodermic pre-filled glass syringe, for example, through covalent bonds or van der Waals bonds, which cause the layer to harden. In some embodiments of the invention, the layer-forming substances can also be cross-linked with one another, forming, for example, a polymer or a polymer-like compound.In an exemplary embodiment of the invention, the coating produced in this way is hydrophobic and / or has improved sliding properties compared to the untreated surface. Preferably, the coating produced can also be chemically inert to gases or liquids with which the hypodermic pre-filled glass syringe comes into contact during intended use.

[0013] According to the invention, in a subsequent method step, at least a partial area of ​​the inner surface of the hypodermic pre-filled glass syringe provided with the coating is subjected to a plasma treatment. For example, the partial area is an inner surface in a syringe cone of the pre-filled glass syringe. This allows the effects of the coating to be at least partially deactivated or reversed without completely removing the coating as such. A plasma, in the sense of the present description, is understood to mean a partially ionized gas which acts on at least a partial area of ​​the coating at a pre-determined pressure and with a pre-determined composition for a specific period of time. In an exemplary embodiment of the invention, the partial area can be as large as the coated inner surface, whereby the plasma acts on the entire previously applied coating on the inner surface.If the coated inner surface encompasses the entire inner surface of the hypodermic pre-filled glass syringe, the plasma can also act on the entire inner surface of the hypodermic pre-filled glass syringe. According to a further exemplary embodiment of the invention, only a portion of the coating is subjected to the plasma treatment, while at least another portion of the coating is not exposed to the plasma. For example, those partial surfaces, such as the partial surface in the syringe cone of the pre-filled glass syringe, which are intended to form a joint in a subsequent process step, can be subjected to the plasma treatment in order to improve the adhesion of adhesives or solder or to enable it in the first place.The plasma is generated, for example, by an atmospheric pressure plasma source, which is positioned in front of one end of the syringe cone in the axial direction in order to introduce the plasma into the interior of the syringe via an end channel or passage formed in the syringe cone.

[0014] A vacuum source is arranged relative to the syringe cone in the axial direction opposite the atmospheric pressure plasma source, wherein the vacuum source provides a negative pressure less than atmospheric pressure in the syringe interior, preferably in the syringe cone interior, in particular in a section of the syringe cone interior. According to an exemplary embodiment, a vacuum is applied as the negative pressure. The application of negative pressure in the syringe interior enables the penetration of the plasma as such and increases the penetration depth of the plasma into the syringe cone, whereby a significantly larger area, in particular that which is subsequently used as an adhesive surface for the cannula or injection needle, can be treated using the atmospheric pressure plasma source.By increasing the plasma-treated surface, the holding forces between the cannula and the glass syringe can be significantly increased. In particular, the adhesion between the adhesive and the glass is significantly increased, which preferably makes it possible to achieve holding forces in accordance with DIN ISO 7864. Furthermore, the arrangement of the vacuum wave to provide negative pressure inside the syringe results in advantageous surface activation for subsequent bonding. Furthermore, other unwanted particles, such as dust or dirt, can be removed from the syringe interior to achieve the cleanest possible surface, i.e., one free of foreign particles. This, in turn, can improve the adhesion of the adhesive to the inner surface of the glass body.

[0015] According to a preferred embodiment of the present invention, a suction mandrel of the vacuum source is introduced into the interior of the glass syringe body, preferably into a piston chamber of the glass syringe body. The piston chamber is understood to be the volume which is delimited from the outside by the glass syringe itself and into which a piston for expelling a substance arranged in the piston chamber, such as a liquid, preferably containing an active ingredient, can be inserted from the outside, in particular in the axial direction from the side of the glass syringe opposite the atmospheric pressure plasma source. Via this suction mandrel, the dimensions of which are adapted to an inner diameter of the glass syringe body, a vacuum of the desired strength can be generated in a targeted manner and as required in the interior of the glass body, preferably in the syringe cone, preferably in a section of the syringe cone.

[0016] According to a further development of the present invention, the suction mandrel is brought into preferably sealed contact with an inner surface and / or a bottom surface of the piston chamber. For example, the suction mandrel can be dimensioned with respect to the inner diameter of the glass syringe, in particular the piston chamber of the glass syringe, such that there is at least partial contact between the suction mandrel and the inner surface of the glass syringe, viewed axially. Alternatively or additionally, it is conceivable to provide a sealing means, such as a sealing ring or a sealing tube, to establish the sealed contact between the inner surface of the glass syringe and the suction mandrel. The sealing means, in particular the sealing ring, is preferably located on a front end of the suction mandrel facing the atmospheric pressure plasma source.

[0017] In an exemplary embodiment of the invention, the action of the plasma reduces the carbon content of the coating to less than about 80%, or less than about 75%, or less than about 70%, or less than about 60% of the initial value before the plasma treatment. The reduction in the carbon content can also have the effect of changing the bonds within the coating. For example, the coating can be converted from a polymeric structure to a glassy or amorphous structure. Alternatively or additionally, the action of the plasma can reduce the layer thickness in the treated partial area. In a further exemplary embodiment of the invention, the layer thickness can be reduced by more than about 20%, or more than about 25%, or more than about 30%. It has been found that the coating is not completely removed by the action of the plasma, or even needs to be removed.Rather, after the plasma treatment, a layer thickness of more than about 70% or more than about 60% or more than about 50% of the layer thickness applied in the first process step may remain in the partial area.

[0018] Furthermore, it was recognized that plasma treatment can change the bonding conditions and / or the layer thickness and / or the element inventory of the originally applied coating in the partial area exposed to the plasma. For example, roughening of the coating and / or hydrophilization can be achieved, so that a subsequent coating or joining process can be facilitated or even made possible in the first place. Furthermore, plasma treatment can be easier to carry out than complete removal of the coating, which may adhere very strongly to the inner surface of the hypodermic pre-filled glass syringe and can only be removed mechanically or wet-chemically. On the one hand, the resulting environmental pollution can be avoided according to the invention and, on the other hand, complex measures to restrict the access of a liquid or gaseous etching medium outside the partial area to be treated can be avoided.

[0019] In an exemplary embodiment of the invention, the layer thickness of the coating, at least in the partial area before exposure to the plasma, is between approximately 20 nm and approximately 100 nm or between approximately 30 nm and approximately 70 nm. Such a coating does not impair the dimensional stability of the coated inner surface of the hypodermic pre-filled glass syringe, but may already be sufficient to bring about improved sliding properties, hydrophobization and / or passivation of the surface.

[0020] According to a further development of the invention, the emulsion and / or the solution can contain or consist of at least one silicone oil and a solvent. For example, the solvent can be water or contain water or contain aliphatic hydrocarbons or aromatics, for example hexane, heptane, toluene and / or xylene. Finally, it is also conceivable for the solvent to also contain an alcohol and / or glycerin and / or ether to form an emulsion. A further exemplary embodiment of the solvent is that it evaporates or is expelled from the resulting coating either under normal ambient conditions or at elevated temperature in a heating cabinet or oven, so that a coating remains on the inner surface or on a partial surface of the coated inner surface of the hypodermic pre-filled glass syringe, which coating contains or consists of silicone.

[0021] In one exemplary embodiment, the coating may contain at least carbon and oxygen and hydrogen and silicon. Furthermore, the coating may contain or consist of at least one polyorganosiloxane. The action of the plasma can at least partially remove the carbon from the coating, so that after the plasma treatment, the coating contains or consists of silicon oxide and / or silicon nitride and / or silicon oxynitride.

[0022] In a further exemplary embodiment, the partial area of ​​the inner surface is hydrophobic before the plasma treatment; the partial area of ​​the inner surface can be hydrophilic before the plasma treatment and hydrophobic after the plasma treatment. For the purposes of the present description, a hydrophobic coating is understood to be a surface which forms a contact angle of more than 90° upon contact with water. For the purposes of the present description, a hydrophilic surface is a surface which forms a contact angle of less than 90° upon wetting with water. The plasma treatment can therefore change the surface energy to such an extent that the adhesive strength or wettability with a lubricant, an adhesive, a solder or a paint increases or is made possible in the first place.

[0023] The plasma may, for example, contain or consist of an active gas. Preferably, the active gas contains or consists of nitrogen and / or oxygen, synthetic air, or atmospheric air.

[0024] In a further exemplary embodiment of the invention, the plasma can be applied for about 0.4 to about 5 seconds, or for about 0.5 to about 4 seconds, or for about 0.5 to about 1.5 seconds, or for about 5 to about 60 seconds. It has been recognized that this short treatment time is already sufficient to convert a hydrophobic silicone coating into a hydrophilic, silicon-containing compound, so that the process according to the present invention can also be used economically in the production of mass products.

[0025] In a further development of the invention, an atmospheric-pressure plasma generated with a dielectric barrier discharge can be used. This allows the method to be easily integrated into existing production processes. On the one hand, this is because the use of a dielectric barrier discharge ensures that the electrical power coupled into the plasma remains limited. On the other hand, thermal damage and / or damage to the coating of the hypodermic pre-filled glass syringe can be avoided.

[0026] In an exemplary embodiment of the invention, a swirling flow of the working gas can be used to generate the plasma. This allows the discharge to be prolonged. In particular, the treatment of the inner surfaces of cylindrical hollow bodies further enhances this effect, as the surfaces present there support the discharge. Slender objects, such as syringes, especially the syringe cone, are thus easier to treat, or even more so, even treatable.

[0027] In an exemplary embodiment of the invention, the plasma may contain or consist of an inert gas. Preferably, the inert gas may be or contain a noble gas. It is also possible for the plasma to contain or consist of argon. An inert gas plasma ensures, in particular, that the components of the coating are not oxidized or reduced or otherwise react with the plasma process gas, so that the coating does not undergo undesired decomposition or is removed from the surface by reactive etching.

[0028] In a further development of the present invention, the plasma can be generated by an alternating voltage or a pulsed voltage having a frequency between about 10 kHz and about 30 kHz or between about 15 kHz and about 25 kHz.

[0029] According to an exemplary embodiment of the invention, a plasma beam can be used, which is generated by an electric field between the surface of the component and at least one counter electrode by ionizing a working gas stream. It is also possible to use a plasma jet, wherein the plasma is generated inside the plasma source by electric fields or electromagnetic radiation and expelled from the source by the working gas stream. In exemplary embodiments of the invention, the plasma is generated with a dielectrically impeded discharge. Plasmas generated in this way exhibit only slight temperature increases of less than approximately 50 K or less than approximately 30 K compared to the ambient temperature, so that thermal damage can be avoided even on sensitive surfaces. This is helpful, for example, when treating components made of a polymer or other plastics.

[0030] In a further development of the present invention, the plasma is generated as a plasma beam or plasma jet, which acts on at least a partial surface of the inner surface of the syringe cone. Furthermore, it can be provided that the plasma acts only when the negative pressure is provided by the negative pressure source.

[0031] According to a further aspect of the present invention, which can be combined with the previous aspects, in a method for producing a hypodermic pre-filled glass syringe with a glass syringe body, which is coated according to the coating method according to the invention described above, and an injection needle, which are joined together or to one another, the injection needle is connected to the glass syringe body along a joint. The joint can comprise the partial area in the syringe cone of the pre-filled glass syringe. The coating or treatment method according to the invention is carried out by arranging an atmospheric pressure plasma source and a vacuum source on the pre-filled glass syringe in such a way that the partial area encompassed by the joint is coated or coated before the injection needle and glass syringe body are joined together.treated, brings about the above-described advantages of the pre-finished glass syringe according to the invention, in particular increased needle holding forces in the syringe body axial direction and / or in particular increased adhesion of the adhesive to the glass syringe body.

[0032] In a further development of the present invention, the joining can be carried out using an adhesive, which is in particular selected from an acrylate and / or polyurethane and / or an epoxy resin and / or a cyanoacrylate. Such adhesives exhibit high adhesive strengths while being easy to process and have high initial strengths, thus enabling rapid production.

[0033] According to a further aspect of the present invention, which can be combined with the previous aspects, a hypodermic pre-filled glass syringe comprises a glass syringe body and an injection needle, which are connected to one another along a joint by an adhesive layer. The joint preferably comprises at least a partial area of ​​an inner surface of a syringe cone of the glass syringe body. The adhesive layer between the joint and the injection needle provides a needle retention force in the axial direction to ensure that the injection needle adheres to the joint during use of the pre-filled glass syringe. According to the invention, at least one atmospheric plasma-treated coating is applied to the inner surface of the syringe cone. The needle retention force is preferably at least (a) 11 N for needle diameter less than 0.33 mm, (b) 22 N for needle diameter less than 0.55 mm, (c) 34 N for needle diameter less than 0.7 mm, (d) 40 N for needle diameter less than 0.8 mm, (e) 44 N for needle diameter less than 0.9 mm, (f) 54 N for needle diameter less than 1.1 mm, and / or (g) 44 N for needle diameter greater than or equal to 1.1 mm.

[0034] The holding forces achieved are sufficient to ensure the strength requirements according to DIN ISO 7864 and thus to achieve sufficient adhesion between the injection needle and the glass syringe body.

[0035] According to an exemplary embodiment of the invention, the layer thickness of the coating, at least in the partial area of ​​the inner surface, before exposure to the plasma is between approximately 20 nm and approximately 100 nm or between approximately 30 nm and approximately 70 nm. As a result of the plasma treatment in the partial area of ​​the inner surface, the layer thickness of the coating can decrease by more than approximately 20%, or more than approximately 25%, or more than approximately 30%. Alternatively or additionally, a layer thickness of more than approximately 70%, or more than approximately 60%, or more than approximately 50% can remain after the plasma treatment of the partial area.

[0036] According to a further aspect of the present invention, the coating may contain at least carbon and oxygen and hydrogen and silicon. Alternatively or additionally, the coating may contain at least one poly(organo)siloxane. Preferably, the carbon content of the coating is reduced to less than about 80%, less than about 75%, less than about 70%, or less than about 60% of the initial value before plasma treatment.

[0037] In a further exemplary embodiment of the pre-filled glass syringe according to the invention, the adhesive is selected from an acrylate and / or a polyurethane and / or an epoxy resin and / or a cyanoacrylate.

[0038] According to a further aspect of the present invention, which can be combined with the previous aspects, a plasma treatment device for glass syringe bodies of hypodermic glass syringes comprises an atmospheric pressure plasma source for providing plasma for treating an inner surface of a syringe cone of the glass syringe body. The glass syringe body is preferably a glass syringe body that has been previously coated with a lubricant layer, such as a silicone layer. For example, the glass syringe body can also have been bake-in siliconized. The plasma treatment can at least partially deactivate or reverse the effect of the coating without completely removing the coating as such. The plasma treatment processes the respective surface, i.e. an inner surface of the glass body, in such a way that the adhesive strength orthe wettability with a lubricant, an adhesive, a solder or a varnish increases or is made possible in the first place.

[0039] The plasma treatment device further comprises a vacuum source for providing a vacuum less than atmospheric pressure. For example, a vacuum can be generated. According to the invention, the atmospheric pressure plasma source and the vacuum source are or can be arranged opposite one another relative to the syringe cone. In particular, the atmospheric pressure plasma source is arranged on the side of the syringe cone at which the liquid contained within the syringe leaves the syringe, and the vacuum source is arranged on the side of the syringe via which the syringe is filled with the liquid. By providing the vacuum source, the penetration of the plasma as such or an increase in the penetration depth into the syringe cone is enabled. This enables a defined treatment of the syringe cone's interior with pure atmospheric plasma.Consequently, the adhesion between the adhesive and the glass can be increased, resulting in a greater holding force between the injection needle or cannula to be attached and the glass syringe. In addition, the provision of negative pressure also creates a sealing effect, as it prevents plasma from entering the syringe body during treatment and causing unwanted treatment of other areas inside the syringe body.

[0040] In an exemplary embodiment of the present invention, the vacuum source of the plasma treatment device comprises a suction mandrel whose outer diameter is less than or equal to the inner diameter of the piston chamber of the glass syringe body, in particular the piston chamber. The suction mandrel serves, for example, for the targeted application of negative pressure and can preferably be designed such that the strength or extent of the negative pressure can be regulated or adjusted via it.

[0041] In a further exemplary embodiment of the plasma treatment device according to the invention, the suction mandrel has an insertion length along which the outer diameter is smaller than the piston chamber inner diameter of the glass syringe body. The insertion length is measured, for example, in the axial direction. The insertion length can be at least as long as the cylinder height of the piston chamber. The plasma treatment device can also be configured to insert the suction mandrel into the piston chamber of the gas tip body in order to apply a negative pressure there. Preferably, the suction mandrel can be inserted into the piston chamber until it touches a bottom surface of the piston chamber. This additionally creates a sealing effect between the glass body inner surface, in particular the bottom surface, and the suction mandrel, in particular to prevent plasma from entering the syringe body during treatment.

[0042] According to a further development of the present invention, the suction mandrel comprises a sealing means, such as a sealing ring and / or a sealing tube. The sealing means is arranged, for example, at the front end, which, viewed in the axial direction, faces the syringe cone. In particular, the sealing means is intended to be brought into contact with an inner diameter, i.e., an inner surface of the piston chamber, and / or a bottom surface of the piston chamber.

[0043] In the following, further properties, features and advantages of the invention will become clear by describing preferred embodiments of the invention with reference to the accompanying exemplary drawings, in which: Fig. 1 shows a cross-sectional view of a hypodermic pre-filled glass syringe according to the invention; Fig. 2 shows a partial cross-sectional view of a hypodermic pre-filled glass syringe according to the invention with a plasma source and a vacuum source; Fig. 3 shows a section of a plasma treatment device according to the invention; Fig. 4 shows an exemplary embodiment of a plasma treatment device according to the invention; Fig. 5 shows an exemplary embodiment of a plasma source; Fig. 6 shows a diagram of an exemplary layer thickness decrease over the treatment time; Fig. 7 shows a further embodiment of a hypodermic pre-filled glass syringe according to the invention; and Fig. 8 shows a further embodiment of a hypodermic pre-filled glass syringe according to the invention.

[0044] In the following illustrations of preferred embodiments, the same or similar reference numerals are used for the same or similar components. A hypodermic pre-filled glass syringe according to the invention is generally designated by reference numeral 7. A plasma treatment device for glass syringe bodies of hypodermic pre-filled syringes according to the invention is generally designated by reference numeral 100.

[0045] In Fig. 1A hypodermic pre-filled glass syringe 7 according to the invention is shown schematically in a sectional view, wherein a glass syringe body 70 of the pre-filled glass syringe 7 is shown hatched. The glass syringe 7 or the glass syringe body 70 essentially comprises a flange section 171 at an end 173 viewed in the axial direction A, an elongated piston section 175 of essentially constant cross-section and constant wall thickness, which adjoins the flange section 171 viewed in the axial direction A, and a syringe cone 72 tapering in cross-section and having a thicker wall thickness, into which the piston section 175 opens in the axial direction A. On the inside, the piston section 175 delimits or defines a piston chamber 107. Adjacent to the syringe cone 72 is a funnel section 177 of the piston section 175, in the interior of which the piston volume 107 tapers like a funnel.A passage 179 extends through the syringe cone 72 essentially in the axial direction A from a syringe cone end 181 opposite the flange end 173 to the piston chamber 107. The passage or end channel 179 has a substantially constant cross-section along its length. At the syringe cone end 181, the passage 179 can be chamfered, for example, with a chamfer at an angle of 45° with respect to the axial direction A, in order to facilitate the subsequent insertion of a cannula or an injection needle and / or an atmospheric pressure plasma source 101, which will be described in detail below. In . Fig. 1a center or symmetry line M is indicated by a dash-dot line, which is oriented essentially parallel to the axial direction A. It can be seen that the pre-filled glass syringe 7 is constructed symmetrically with respect to the center line M. On the inside, i.e. on an inner surface 21 of the pre-filled glass syringe 7, a coating 3, which is preferably designed as a baked-on silicon coating, is applied. This ensures in particular that a piston 71 to be inserted, which is described in more detail below, can be pushed along the inner surface 21 of the glass syringe 7 with as little friction as possible and thus with good sliding. A partial surface 22 of the inner surface 21, which, as particularly in Fig. 1can be seen, forms at least part of the syringe cone inner surface or the inner surface of the passage 179, is primarily intended as a later adhesive surface for the injection needle 73 or cannula 76 to be glued in. It should be understood that the partial surface 22 with the coating 3 is also treated by the atmospheric pressure plasma source 101. Furthermore, it is preferably the partial surface 22 which is treated using the coating method according to the invention with the vacuum source 103 in order to process the partial surface 22 in such a way that increased adhesion of the adhesive used for bonding is achieved. The treatment of the syringe interior with the atmospheric pressure plasma source 101 and the vacuum source 103 is described with reference to Fig. 2 to 4 described in more detail.

[0046] The flange portion 171 has at least one flange web 183 extending at least partially in the circumferential direction and extending perpendicular to the axial direction away from the central axis M, which is provided for actuation by a user with the fingers.

[0047] In Fig. 2 A section of a pre-finished glass syringe 7 according to the invention is shown schematically, wherein an atmospheric pressure plasma source 101 is arranged at the syringe cone-side end 181 and a vacuum source 103 is located inside the piston chamber 107 on the piston section side. Regarding the details of a preferred embodiment of the atmospheric pressure plasma source 101, Fig. 5 referred to. In Fig. 2This is shown only as a block, schematically indicating that a plasma jet 4 is introduced via the syringe cone-side end 181 into the end channel 179 in the syringe cone 72 in order to treat the inner surface 21 as well as the partial surface 22 with the plasma jet 4. According to the invention, the plasma treatment of the inner surfaces of the pre-filled glass syringe 7 is combined with the application of a vacuum source 103, preferably in the syringe interior. Fig. 2only one suction mandrel 105 is shown, inserted into the piston chamber 107 of the glass syringe body 70. In the illustrated position of the suction mandrel 105 relative to the glass syringe body 70, the suction mandrel 105 is in contact with an inner side 109 of the glass syringe body 70, which is a sliding contact, and a partially funnel-shaped bottom surface 111 of the piston interior 107, which prevents further insertion of the suction mandrel 105 into the piston chamber 107. According to the embodiment in Fig. 2A sealing ring 119 is arranged on a front end 123 of the suction mandrel 105 facing in the axial direction A towards the bottom surface 111, in particular to provide a sealing contact with the bottom surface 111. Alternatively or in addition to the sealing ring 119, a sealing tube (not shown) can also be attached to the suction mandrel to provide an additional sealing effect. It can be seen that the vacuum source 103 or the suction mandrel 105 of the vacuum source 103 generates a vacuum less than atmospheric pressure in the region of the syringe cone 72, i.e. essentially in the passage 179, in order to subject the partial surface 22 of the inner surface 21 of the pre-finished glass syringe 7 to both atmospheric pressure plasma and negative pressure. This results in the advantageous change in properties according to the invention on the partial surface 22 in order to enable the subsequent bonding of the injection needle 73 or the cannula 76.and to increase the holding force with respect to the inside of the glass body 22 in the axial direction A.

[0048] In Fig. 3A section of a plasma treatment device 100 for glass syringe bodies 70 of hypodermic pre-filled glass syringes 7 is shown in a side view. The plasma treatment device 100 comprises a support frame 185, on which at least one gripper 187 is arranged for gripping or holding a glass syringe body 70 of a hypodermic pre-filled glass syringe 7. The gripper 187 extends, viewed in the axial direction A, approximately three-quarters of the complete longitudinal extent of the glass syringe body 70. However, the gripper 187 can also extend, for example, by 15%, 30%, 45%, 60%, or even between 80% and 100% of the complete longitudinal extent of the glass syringe body 70 in the axial direction A. The gripper has a substantially constant cross-sectional shape, with an elongated chamfer 189 being formed over the entire circumference of the gripper 187 at the end facing away from the support frame 185.The gripper 187 has essentially a cylindrical shape, wherein essentially along its entire longitudinal extent, ie in the axial direction A in . Fig. 3 , a slot 191 is provided for the lateral insertion of a glass syringe body 70. In the assembled state of the glass syringe body 70 in the gripper 187, the gripper 187 grips the glass syringe body 70 in a clamp-like manner, with an inner diameter of the gripper 187 approximately corresponding to the outer diameter of the glass syringe body 70, it being clear that the inner diameter of the gripper 187 should not be smaller than the outer diameter of the glass syringe body 70. However, it is possible to provide a press fit between the glass syringe body 70 and the gripper 187. Furthermore, the gripper 187 has two grooves 193 near the support frame 185, running perpendicular to the axial direction A, into which the flange section 177 of the glass syringe body 70 is to be inserted. As shown in particular in Fig. 3As can be seen, the dimensions of the slots 193 are selected such that the flange section 171 is accommodated appropriately. A slot 193 is provided in the gripper 187 on both sides relative to the glass syringe body 70.

[0049] An atmospheric plasma pressure source 101 of the plasma treatment device 100 is arranged below the glass syringe body 70 for providing plasma for treating an inner surface 21 of the glass syringe body 70, wherein the reference number 4 indicates a plasma jet directed into the syringe interior. The atmospheric pressure plasma source 101 is referred to Fig. 5 (explained in more detail below).

[0050] A vacuum source 103 for providing a vacuum less than atmospheric pressure can be arranged on the support frame 185 itself. The atmospheric pressure source 101 and the vacuum source 103 can be arranged opposite one another relative to the syringe cone 72 of the glass syringe body 70, so that the vacuum for the inventive treatment of at least a partial surface 22 of the inner surface 21 of the glass syringe body 70 can be conducted in the syringe cone 72. The vacuum source 103 can, for example, also be mounted in a position other than on the support frame 185, wherein at least one applicator, such as a suction mandrel 105 of the vacuum source 103, must be arranged opposite the atmospheric pressure plasma source 101 relative to the syringe cone 72. As shown in Fig. 3As shown, the vacuum source 103 has a suction mandrel 105 with an outer diameter less than or equal to the piston chamber inner diameter 113 of the glass syringe body 70, so that the latter can be brought into the treatment position according to the invention. Furthermore, in Fig. 3 It can be seen that the suction mandrel 105 has an insertion length 115, along which the outer diameter is smaller than the piston chamber inner diameter 113 of the glass syringe body 70. In Fig. 3 The suction mandrel 105 is inserted until it touches a bottom surface 111 of the piston chamber 107. In other words, a front end 123 of the suction mandrel 105 is pushed so far into the piston chamber that the front end 123 rests on the bottom surface 111 of the piston chamber 107.

[0051] The presence of a sealing means, such as a sealing ring 119 and / or a sealing hose (not shown), which is to be arranged, for example, on the front end 123 of the suction mandrel 105, can be advantageous in order to be brought into sealing contact with the inner side 109 and / or the bottom surface 111 of the piston chamber 107.

[0052] In Fig. 4 An exemplary embodiment of a plasma treatment device 100 according to the invention is shown. In the following description, only those components are described which have not already been described in relation to the previous Fig. 1 to 3The exemplary plasma treatment device 100 has a plasma source arrangement 195 of four atmospheric pressure plasma sources 101 for the simultaneous or sequential treatment of glass syringe bodies 70 of hypodermic pre-filled glass syringes 7. At least five and, for example, a maximum of 30 glass syringe bodies 70 of hypodermic glass syringes 7 can be attached to the support frame 185, which can consist, for example, of three longitudinal struts 197 mounted on one another, in order to treat them by means of the plasma treatment device 100. Furthermore, the plasma treatment device 100 is designed such that vacuum sources 103 are provided corresponding to the number of glass syringe bodies 70 that can be accommodated, or suction mandrels 105 of a common or separate vacuum source 103.

[0053] On a stand 199, which can be designed, for example, like a door frame or archway, at least one or three identically designed ( Fig. 4), a sensor device 201 is attached, which serves to detect whether a glass syringe body 70 is located in a gripper 187 of the support frame 185. Based on this information, the atmospheric pressure plasma source 101 and the vacuum source 103 by means of which the corresponding glass syringe body 70 can be treated can then be controlled. For example, the sensor device 201 is designed as a laser device 203 and has a laser beam generator 205, which is attached to the stand 199, and a reflection device 207, for example a mirror device, for reflecting a laser beam 209 generated by the laser device 205. It is clear that further sensor devices 201 are conceivable, which are capable of detecting whether a glass syringe body 70 is located in a respective holder 187 of the support frame 185.

[0054] Based on Fig. 5A plasma source suitable for carrying out the coating method described above is explained in more detail. It is embodied, for example, as an atmospheric pressure plasma source 101. The atmospheric pressure plasma source 101 comprises a high-voltage electrode 52 surrounded by an insulator 53. The high-voltage electrode 52 is embodied as a hollow body and can be cylindrical or conical, for example. The insulating body 53 is arranged at a distance from the high-voltage electrode 52. In this way, a working gas can be introduced into the gap 155 between the high-voltage electrode 52 and the insulating body 53, which can be supplied via a gas supply 54.The working gas leaves the high-voltage electrode 52 via its substrate-side mouth 157, which is funnel-shaped and has a cross-section that decreases in its longitudinal direction and defines an outlet opening 159 through which the working gas can leave the mouth 157.

[0055] Opposite the orifice 157 is a counterelectrode 51, which can optionally be provided with a dielectric coating. This ensures that a dielectrically impeded discharge is always ignited between the high-voltage electrode 52 and the counterelectrode 51. If the substrate itself contains or consists of a dielectric or insulator, the dielectric coating of the counterelectrode 51 can also be omitted.

[0056] During operation of the device, a working gas, for example argon, is supplied via gas supply 54. A high-frequency alternating voltage, generated by a high-voltage source 55, is applied to the high-voltage electrode 52. In some embodiments of the invention, the amplitude of the applied high voltage can be between approximately 2 kV and approximately 10 kV or between approximately 5 kV and approximately 8 kV. The high voltage can be applied as a sinusoidal alternating voltage or in the form of individual high-voltage pulses. The pulse repetition frequency or the alternating voltage frequency can be between approximately 10 Hz and approximately 30 kHz. The power converted in the plasma 4 can be determined using a measuring capacitor, which integrates the transferred charge carriers of a discharge cycle. The power determined in this way can be between approximately 0.5 watts and approximately 5 watts or between approximately 1 watt and approximately 3 watts.

[0057] The plasma jet generated in this way has a diameter of approximately 0.15 mm to approximately 0.5 mm. Upon impact with an exemplary component 2, the base point widens, so that the partial area 22 can be larger than the diameter of the plasma jet 4. If the partial area 22 is larger than the beam spot resulting from the geometry of the plasma source, a larger partial area 22 can be processed by sequential treatment with the plasma 4 by moving the component 2 or the counter electrode 51 with the component 2 arranged thereon. The distance of the beam exit from the surface to be treated can be between approximately 3 mm and approximately 8 mm.

[0058] Based on Fig. 6 The elipsometrically determined reduction in the thickness of the partial area 22 by the plasma treatment is explained. The treatment time is determined by the Fig. 5explained plasma beam 4 is plotted on the abscissa and the elipsometrically determined layer thickness is plotted on the ordinate.

[0059] How Fig. 6 shows, the layer thickness before exposure to the plasma is 110 nm. After an exposure time of about 10 seconds, the layer thickness already decreases to about 75 nm. After 30 s, the layer thickness is about 57 nm. With a very long treatment time of 300 seconds, the layer thickness decreases to about 50 nm. The layer thickness shows an asymptotic progression with the treatment time. Fig. 6 The measured values ​​shown suggest that the layer thickness does not fall below 50 nm even with longer treatment times.

[0060] This shows Fig. 6that the plasma treatment of the coating according to the invention does not achieve complete removal of the coating. Nevertheless, the chemical composition and / or the bonding relationships of the constituents within the coating change, as will be explained in more detail below. This is accompanied by a change in the wetting behavior. The second partial surface 22 treated with the plasma is no longer hydrophobic as originally, but hydrophilic, so that the partial surface 22, after exposure to the plasma 4, is suitable for being joined by means of an adhesive bond or for being coated again with a different coating material.

[0061] The Fig. 6The measured values ​​shown were determined using a coating 3 obtained by bake-in siliconization. For this purpose, an emulsion of silicone oil and water is applied and subsequently baked onto the surface of component 2 using a heat treatment. The following table shows the element inventory of coating 3 before exposure to the plasma, after 1 second, 10 seconds, 30 seconds, 60 seconds, and after 300 seconds. All measured values ​​were obtained using photoelectron spectroscopy. In this process, monochromatic X-rays are irradiated onto the surface of coating 3, and the kinetic energy of the photoelectrons is determined. The respective element can be determined from the kinetic energy; the intensity of the photoelectrons indicates the relative proportions in coating 3. Table 1: Element inventory of the coating element 0 s [atomic %] 1 s [atomic %] 10 s [atomic %] 30 s [atomic %] 60 s [atomic %] 300 s [atomic %] Oxygen (O) 39,1 56,2 60,4 67 66,96 66,96 Carbon (C) 35,8 18,93 13,9 5,6 4,14 3,63 Silicon (Si) 25,1 24,85 25,7 27,4 28,68 29,28 rest -- -- -- -- 0,27 0,13

[0062] The measurements were obtained after exposure to an atmospheric pressure plasma jet 4 with atmospheric air as the working gas, which can be produced, for example, with the device according to Fig. 5 is available. As the measured values ​​presented above show, the carbon content of the coating decreases rapidly with increasing exposure time to the plasma. This is due to the fact that the methyl groups contained in the silicone are split off and carried away by the gas flow of the working gas of plasma 4.

[0063] In order to increase the needle retention force between the injection needle 73 and the pre-filled glass syringe 7, in particular to ensure strength values ​​within the framework of DIN ISO 7864, the inventive method step of arranging a vacuum source 103 opposite the atmospheric pressure plasma source 101, viewed relative to the syringe cone 72, is used. After treatment with plasma 4, the coating of a partial surface 22 is processed while simultaneously applying negative pressure by the vacuum source 103 in such a way that subsequent adhesion of an adhesive to be applied to the partial surface 22 is significantly increased, thereby increasing the retention force between the cannula 76 or injection needle 73 and the pre-filled glass syringe 7.

[0064] Fig. 7shows a pre-filled syringe, exemplified as a pre-filled glass syringe 7, as a further embodiment of the invention. The pre-filled glass syringe 7 has an approximately cylindrical syringe body 70. Pre-filled glass syringes 7 of the type shown serve as packaging for the medication contained therein in the manufacturing plant, so that it can be handed over to the doctor or patient immediately ready for use.

[0065] For the production (not shown) of the Fig. 7 In the pre-made glass syringe 7 shown, the syringe body 70 is first manufactured from a glass tube. For this purpose, the glass tube is cut to size, heated, and formed into the desired shape.

[0066] In the next process step, at least the inside is treated with an emulsion consisting of a solvent and layer-forming substances, such as by spraying, and subsequently treated in an oven or heating cabinet. This causes a large portion of the solvent present in the emulsion to evaporate. At the same time, the silicone contained as a layer-forming substance is covalently bonded to the glass, forming a coating 3 on the inside that contains or consists of polysiloxane. The heat treatment prevents the silicone from undesirably migrating into the medication during subsequent filling, storage, and use of the pre-filled glass syringe 7. At the same time, the siliconization allows the plunger 7 to slide easily, thus making handling of the pre-filled glass syringe 7 easier.

[0067] In the illustrated embodiment, a cone 72 is glued to the end of the syringe body 70 opposite the piston 71, which cone is provided for receiving the injection needle 73. In other embodiments of the invention, the injection needle 73 can also be glued directly into the syringe body 70, so that the cone 72 can be omitted, or alternatively, the cone 72 can be made in one piece with the glass syringe body 70.

[0068] Since the coating 3 also covers the partial surface 22 intended to receive the cone 72, the adhesive strength of an adhesive bond 6 is reduced. This can go so far that the cone 72 falls out of the syringe body 70 during transport or storage, and the contents of the pre-filled glass syringe 7 leak out.

[0069] According to the invention, it is therefore proposed to treat the partial surface 22 with an atmospheric pressure plasma in the manner described above, thereby not completely removing the coating 3, but inactivating it to such an extent that the adhesive bond 6 can be reliably filled. This is achieved according to the invention by applying a vacuum source 103, which is arranged relative to the syringe cone 72 in the axial direction A opposite the atmospheric pressure plasma source 101 and provides a vacuum less than atmospheric pressure. By changing the element inventory and / or the bonding ratios of the constituents, the hydrophobic coating 3 in the partial surface 22 can become hydrophilic in order to significantly improve the adhesive strength of the bond 6 or to provide needle holding forces in the axial direction A that meet the requirements of DIN ISO 7864.

[0070] Fig. 8shows a pre-filled syringe, which can also be designed, for example, as a pre-filled glass syringe 7, and whose basic function has already been explained with reference to the previous embodiments. Identical components are provided with the same reference numerals, so the following description is limited to the essential differences.

[0071] For the production of Fig. 8 In the pre-made glass syringe 7 (staked-in-needle syringe) shown, the syringe body 70 is first manufactured from a glass tube. For this purpose, the glass tube is cut to size, heated, and formed into the desired shape. However, the syringe body 70 can also be made of plastic (not shown). Plastic syringes are manufactured using known manufacturing processes, e.g., injection molding.

[0072] In the next process step, at least the inside of the syringe body 70 is sprayed with an emulsion consisting of a solvent and layer-forming substances and subsequently treated in an oven, e.g. a tunnel oven or heating cabinet. This causes a large portion of the solvent present in the emulsion to evaporate. At the same time, the silicone contained as a layer-forming substance is largely covalently bound to the glass, so that a coating 3 is formed on the inside, i.e. on the inner surface 21 including the partial surface 22, which coating contains or consists of polysiloxane and / or polydimethylsiloxane. The heat treatment prevents the silicone from undesirably migrating into the medication during later filling, storage, and use of the pre-filled glass syringe 7. At the same time, the siliconization allows the plunger stopper 75 to slide easily, so that the handling of the pre-filled glass syringe 7 orapplication of the medication is made easier or even possible in the first place.

[0073] In the illustrated embodiment, a cannula 76 is glued to the end of the syringe body 70 opposite the plunger stopper 75. Since the coating 3 also covers the partial surface 22 intended to receive the cannula 76, the adhesive strength of an adhesive connection 6 is reduced. This can go so far that the cannula 76 falls out of the syringe body 70 during transport or storage, and the contents of the pre-filled glass syringe 7 leak out.

[0074] According to the invention, it is therefore proposed to treat the partial surface 22 according to the coating method according to the invention described above using an atmospheric pressure plasma source 101 and a vacuum source 103, which according to the invention are arranged opposite one another in the axial direction A with respect to the syringe cone 72, and wherein the vacuum source 103 provides a vacuum, in particular in the syringe cone 72, which is less than atmospheric pressure in order to increase the adhesiveness of the adhesive to the partial surface 22 of the inner surface 21 of the pre-finished glass syringe 7, so that a holding force is achieved between the cannula or injection needle 73 and the glass syringe 7 in accordance with DIN ISO 7864. By changing the element inventory and / or the bonding ratios of the constituents, the hydrophobic coating 3 in the second partial surface can become hydrophilic, thus improving the adhesive strength of the adhesive bond 6.

[0075] After the cannula 76 has been glued into the syringe body 70, the pre-filled glass syringe 7 is prepared for filling in a conventional manner, i.e., cleaned, sterilized, and packaged. At this time, the needle guard 74 is also placed on the cannula 76. The syringe, prepared for filling in this way, is then delivered to the drug manufacturer for filling.

[0076] The features disclosed in the above description, the figures and the claims may be important both individually and in any combination for the realization of the invention in the various embodiments. List of reference symbols

[0077] 2Component 3Coating 4Plasma 6Adhesive joint 7Finished glass syringe 21Inner surface 22Partial surface 51Counter electrode 52High-voltage electrode 53Insulator 54Gas supply 55High-voltage source 70Glass syringe body 71Piston 72Syringe cone 73Injection needle 74Needle guard 75Piston plug 76Cannula 100Plasma treatment device 101Atmospheric pressure plasma source 103Vacuum source 105Suction mandrel 107Piston chamber 109Inside 111Bottom surface 113Piston chamber inner diameter 115Insertion length 119Sealing ring 123Front end 155Gap 157Mouth 159Exit opening 171Flange section 173Flange end 175Piston section 177Funnel section 179Passage or end channel 181Syringe cone end 183Flange web 185Support frame 187Gripper 189Bevel 191, 193Slot 197Longitudinal strut 199Stand 201Sensor device 203Laser device 205Laser beam generator 207Reflection device 209Laser beam A Axial direction M Central axis

Claims

1. A method for coating a glass syringe body (70) for a hypodermic pre-filled glass syringe (7), in which at least one emulsion and / or a solution containing at least one film-forming substance is applied to at least one inner surface (21, 22) of the hypodermic pre-filled glass syringe (7), which defines an axial direction (A), wherein at least one partial surface (22) of the inner surface (21) in a syringe cone (72) of the pre-filled glass syringe (7) is subsequently exposed to a plasma (4), characterized in that a vacuum source (103) is arranged relative to the syringe cone (72) in the axial direction (A) opposite to an atmospheric pressure plasma source (101), wherein a vacuum less than atmospheric pressure is provided by means of the vacuum source (103).

2. The method according to claim 1, wherein a suction mandrel (105) of the vacuum source (103) is introduced into a piston chamber (107) of the glass syringe body (70).

3. The method according to claim 2, wherein the suction mandrel (105) is brought into a preferably sealing contact with an inner side (109) and / or a bottom surface (111) of the piston chamber (107).

4. The method according to any one of claims 1 to 3, characterized in that the carbon content of the coating (3) decreases to less than about 80% or less than about 75% or less than about 70% or less than about 60% of the initial value before the plasma treatment and / or that the layer thickness of the coating (3) at least in the partial surface (22) of the inner surface (21) before the action of the plasma is between about 20 nm and about 100 nm or between about 30 nm and about 70 nm and decreases by more than about 20% or more than about 25% or more than about 30% due to the plasma treatment in the partial surface (22) and / or that after the plasma treatment in the partial surface (22) a layer thickness of more than about 70% or more than about 60% or more than about 50% remains.

5. The method according to any one of the preceding claims, characterized in that the emulsion and / or the solution contains or consists of at least a silicone oil and optionally water and / or that the coating (3) contains at least carbon and oxygen and hydrogen and silicon and / or that the coating (3) contains at least a poly(organo)siloxane.

6. The method according to any one of the preceding claims, characterized in that the partial surface (22) of the inner surface (21) of the syringe cone (72) is hydrophobic before the plasma treatment and hydrophilic after the plasma treatment.

7. The method according to any one of the preceding claims, characterized in that the plasma (4) contains or consists of an active gas and that the active gas optionally contains or consists of oxygen or synthetic air or atmospheric air.

8. The method according to any one of the preceding claims, characterized in that the plasma (4) acts for about 0.4 to about 5 seconds or for about 0.5 to about 4 seconds or for about 0.5 to about 1.5 seconds or for about 5 to about 60 seconds and / or that an atmospheric pressure plasma is used, which is generated with a dielectric barrier discharge and / or that the plasma (4) contains or consists of an inert gas and that the inert gas optionally contains or consists of a noble gas, in particular argon, and / or that the plasma is formed as a plasma beam or plasma jet, which acts at least on the partial surface (22) of the inner surface (21) of the syringe cone (72) and / or the plasma (4) acts while the vacuum is provided.

9. A method for manufacturing a hypodermic pre-filled glass syringe (7) with a glass syringe body (70), which is coated with a method according to any one of claims 1 to 7, and an injection needle (73), which are joined together, wherein the injection needle (73) is connected to the glass syringe body (70) along a joining point (6) by means of an adhesive, wherein the joining point (6) comprises the partial surface (22) in the syringe cone (72) of the pre-filled glass syringe (7).

10. The method according to claim 9, characterized in that the adhesive is selected from an acrylate and / or a polyurethane and / or an epoxy resin and / or a cyanoacrylate.

11. A plasma treatment device (100) for glass syringe bodies (70) of hypodermic pre-filled glass syringes (7), comprising: an atmospheric pressure plasma source (101) for providing plasma for treating an inner surface (21) of a syringe cone (72) of the glass syringe body (70) and a vacuum source (103) for providing a vacuum less than atmospheric pressure, wherein the atmospheric pressure plasma source (101) and the vacuum source (103) are arrangeable relative to the syringe cone (72) opposite each other.

12. The plasma treatment device (100) according to claim 11, wherein the vacuum source (103) has a suction mandrel (105) with an outer diameter less than or equal to an inner diameter of the piston chamber (113) of the glass syringe body (70), in particular of the piston chamber (107).

13. The plasma treatment device (100) according to claim 12, wherein the suction mandrel (105) has an insertion length (115) along which the outer diameter is less than the inner diameter of the piston chamber (113) of the glass syringe body (70), wherein the insertion length (115) is at least as long as the cylinder height (117) of the piston chamber (107), wherein in particular the plasma treatment device (100) is arranged to introduce the suction mandrel (105) into the piston chamber (107) of the glass syringe body (70) preferably up to a contact with a bottom surface (111) of the piston chamber (107).

14. The plasma treatment device (100) according to claim 12 or 13, wherein the suction mandrel (105) comprises a sealing means, such as a sealing ring (119) and / or a sealing hose, which is preferably arranged at least at the front end (123) of the suction mandrel (105), in particular to be brought into a preferably sealing contact with an inner side (109) and / or a bottom surface (111) of the piston chamber (107).